Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD8205 + saruparib
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous (AZD8205, Anticipated), Oral (saruparib, Anticipated)
01
Overview
AZD8205 + saruparib is a combination of two investigational anticancer drugs being studied in clinical trials for the treatment of advanced or metastatic solid tumors, including but not limited to breast cancer, biliary tract cancer, ovarian cancer, endometrial cancer, and squamous non-small cell lung cancer. AZD8205 is an antibody-drug conjugate (ADC), designed to selectively deliver a cytotoxic payload to cancer cells expressing a specific target, leading to tumor cell death. Saruparib (AZD5305) is a next-generation PARP inhibitor that impairs DNA repair in cancer cells, resulting in synthetic lethality and cell death, particularly in tumors with defects in homologous recombination repair pathways. The combination aims to enhance anticancer efficacy by targeting cancer cells through distinct and potentially synergistic mechanisms[1][2][3].
- Other names
- AZD8205 + AZD5305AZD8205 + saruparib
02
Targets
VTCN1 (V-set domain containing T cell activation inhibitor 1)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on AZD8205 + saruparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD8205 + saruparib.